STAT17h
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
FierceBiotech18h
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
BioSpace15h
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
FierceBiotech1d
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Denali Therapeutics (NASDAQ:DNLI) Given New $87.00 Price Target at HC Wainwright
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...
ALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Denali Therapeutics: Strategic Pipeline Potential and Investment Opportunity Amid Recent Setbacks
Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price ...
BioPharma Dive13h
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...